NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer

July 5, 2019
Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …

Scientists use cold virus to treat bladder cancer

July 5, 2019
Medical Communications, Research and Development CVA21, Cancer, bladder cancer, oncology, oncolytic, pharma, virus

A strain of the virus that causes the common cold has been found to potentially target, infect and kill cancer …

dw-anzcxqaqavhl

FDA approves multiple myeloma therapy Xpovio despite safety concerns

July 4, 2019
Sales and Marketing FDA, Karyopharm, Xpovio, multiple myeloma, pharma

The FDA has made the controversial decision to approve the nuclear export inhibitor Xpovio (selinexor) from Karyopharm Therapeutics, in combination …

Cancer cost US more than $94 billion in lost earnings in 2015

July 4, 2019
Research and Development Cancer, economics, health, lost earnings, oncology, pharma

Cancer deaths cost the US economy $94.4 billion in lifetime earnings in 2015, according to figures from the American Cancer …

shutterstock_138095450_13

Prices hiked on 3,400 drugs in first half of 2019

July 4, 2019
Research and Development, Sales and Marketing abstruse, access, generics, pharma, prescription, pricing

There have been price hikes on more than 3,400 drugs in the United States in the first six months of …

alexion_sign

European approval for Alexion’s Ultomiris in rare blood disease

July 4, 2019
Sales and Marketing Alexion, Europe, Ultomiris, paroxysmal nocturnal haemoglobinuria

Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …

medicinal_cannabis_uk_review

UK Government call for more research into medicinal cannabis

July 4, 2019
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CBMP, Marijuana, UK, medicinal cannabis, pharma, politics

The British government has called for more research into cannabis-based medicinal products (CBMPs). In a paper published on 3 July, …

landing-hero-images1

ViiV’s Dovato approved in Europe as treatment option for HIV-1

July 3, 2019
Research and Development, Sales and Marketing Dovato, GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen …

1920px-hiv-budding-color

Researchers use gene-editing tool CRISPR to cure mice of HIV

July 3, 2019
Research and Development AIDS, HIV, Nature Communications, crispr, mice, pharma

American scientists have been able to combine a new form of antiretroviral therapy (ART) with gene editing tool CRISPR/Cas9 to …

Roche’s Xofluza proves non-inferior to Tamiflu in children with flu

July 3, 2019
Research and Development Roche, Tamiflu, flu, pharma

Roche has unveiled new Phase 3 data indicating that Xofluza (baloxavir marboxil) was well-tolerated and of comparable efficacy to its …

US Government awarded new patent on preventative HIV drugs PrEP

July 3, 2019
Research and Development, Sales and Marketing Gilead, HHS, government, pharma

The Department of Health and Human Services (HHS) has been awarded a new patent on drugs that prevent HIV. The …

Elizabeth Warren calls on former FDA commissioner Scott Gottlieb to resign from board of Pfizer

July 2, 2019
Research and Development FDA, Pfizer, Scott Gottlieb, health, pharma, public health

Democrat Presidential candidate Elizabeth Warren has criticised Scott Gottlieb for joining Pfizer.   In a letter to Gottlieb, Senator Warren …

Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy

July 2, 2019
Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy

Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …

shutterstock_138095450

UK industry spend on R&D collaborations grows to £377.3 million

July 2, 2019
Manufacturing and Production, Medical Communications, Research and Development ABPI, R&D, pharma

The Association of the British Pharmaceutical Indusxtry (ABPI) has unveiled new data showed that UK industry investment in R&D collaborations …

Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer

July 2, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq

Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …

shutterstock_158366573

Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma

July 2, 2019
Manufacturing and Production, Sales and Marketing Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma

The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) …

Hospitals in Oxfordshire to test for susceptibility to dangers of chemotherapy

July 1, 2019
Manufacturing and Production Cancer, Diagnostics, NHS, UK, breast, colon, oesophogus, pharma

Hospitals in Oxfordshire have introduced a genetic test which helps doctors predict the dangerous side effects of chemotherapy.   In …

Living with mal de debarquement syndrome

July 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing patient experience, pharma, rare disease

Polly Moyer reflects on her experiences living with the rare condition mal de debarquement syndrome, and discusses how connecting with …

janssen_latest_logo_on_sign

Janssen secures two positive CHMP opinions for Imbruvica label expansions

July 1, 2019
Sales and Marketing CHMP, EMA, Europe, Janssen, imbruvica, pharma

Janssen’s Imbruvica (ibrutinib) has racked up two positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human …

novartis_window

Novartis says it did not send substances for chemical weapons to Syria

July 1, 2019
Sales and Marketing Brenntag, Novartis, Syria, chemical weapons, pharma, war

Swiss firm Novartis has said that it did not send chemicals that could be used to make chemical weapons to …

The Gateway to Local Adoption Series

Latest content